Treats hypertension. ANDA 203835, held by Hetero Labs. Losartan Potassium.
As of Nov 21, 2026, ANDA 203835 (Losartan Potassium), held by Hetero Labs, was first approved by FDA on Aug 12, 2015, with 4 approved supplements and 0 published complete response letters.
Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 12, 2015 | Original application | Approved |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Dec 16, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Jul 14, 2022 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 4, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 10, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 12, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters